Amanda Baine
Family · Enterprise, ALNPI 1528663275
Payments from drug & device makers
Across 283 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$823
- Lilly USA, LLC$592
- Otsuka America Pharmaceutical, Inc.$343
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$318
- Amgen$317
- Pfizer$277
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,82599%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 46 | $823 |
| Lilly USA, LLC | 51 | $592 |
| Otsuka America Pharmaceutical, Inc. | 18 | $343 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $318 |
| Amgen | 19 | $317 |
| Pfizer | 17 | $277 |
| AbbVie | 17 | $274 |
| Corium, LLC | 11 | $267 |
| Alkermes, Inc. | 14 | $267 |
| AstraZeneca | 14 | $229 |
| Neurocrine Biosciences, Inc. | 8 | $172 |
| Boehringer Ingelheim | 8 | $129 |
| Indivior Inc. | 4 | $101 |
| Bayer | 5 | $97 |
| Lundbeck LLC | 4 | $74 |
| Novo Nordisk | 4 | $66 |
| Esperion Therapeutics, Inc. | 3 | $63 |
| Exact Sciences | 4 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| Merck | 4 | $56 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Acadia Pharmaceuticals Inc | 2 | $29 |
| Seqirus USA Inc | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| GSK | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
How this compares
$4,874 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $70,640 |
| FarxigaDapagliflozin Propanediol | 48 | $68,105 |
| MounjaroTirzepatide | 47 | $63,658 |
| JardianceEmpagliflozin | 55 | $49,696 |
| RybelsusSemaglutide | 29 | $43,668 |
| EliquisApixaban | 48 | $39,430 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $32,253 |
| XareltoRivaroxaban | 34 | $31,526 |
| JanuviaSitagliptin Phosphate | 25 | $21,843 |
| KerendiaFinerenone | 19 | $20,961 |
| MyrbetriqMirabegron | 21 | $14,609 |
| LinzessLinaclotide | 16 | $13,591 |
| EntrestoSacubitril/Valsartan | 11 | $13,133 |
| Repatha SureclickEvolocumab | 16 | $8,618 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $4,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $66 | $114,30884 claims |
| AstraZenecaFarxiga, Symbicort | $229 | $70,88159 claims |
| Lilly USA, LLCMounjaro | $592 | $63,65847 claims |
| Boehringer IngelheimJardiance | $129 | $49,69655 claims |
| PfizerEliquis | $277 | $39,43048 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $19 | $36,32256 claims |
| Johnson & JohnsonXarelto | $823 | $31,52634 claims |
| MerckJanuvia | $56 | $21,84325 claims |
| BayerKerendia | $97 | $20,96119 claims |
| AbbVieLinzess | $274 | $13,59116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.
Other family in Enterprise
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.